Kidswell Bio Corporation (TYO:4584)

Market Cap	11.46B +131.9%
Revenue (ttm)	7.06B +276.4%
Net Income	23.97M
EPS	0.51
Shares Out	49.62M
PE Ratio	478.18
Forward PE	13.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	443,300
Average Volume	448,670
Open	232.00
Previous Close	231.00
Day's Range	222.00 - 233.00
52-Week Range	124.00 - 417.00
Beta	1.16
RSI	37.59
Earnings Date	May 14, 2026

About Kidswell Bio

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 37
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4584

Financial Performance

In fiscal year 2025, Kidswell Bio's revenue was 5.08 billion, an increase of 223.90% compared to the previous year's 1.57 billion. Losses were -21.00 million, -96.07% less than in 2022.